Invest with Confidence:
- Follow TipRanks' Top Wall Street Analysts to uncover their success rate and average return.
- Join thousands of data-driven investors – Build your Smart Portfolio for personalized insights.
AstraZeneca ( (GB:AZN) ) has shared an update.
AstraZeneca and Daiichi Sankyo’s Enhertu has received FDA approval in the US for treating patients with HR-positive, HER2-low or HER2-ultralow metastatic breast cancer after disease progression on endocrine therapies. This approval, based on the DESTINY-Breast06 Phase III trial results, marks a significant advancement by allowing a new treatment option that offers a median progression-free survival of over a year, positioning Enhertu as a potential new standard of care and broadening the patient population eligible for HER2-directed therapies.
More about AstraZeneca
AstraZeneca is a global, science-led biopharmaceutical company that primarily focuses on the discovery, development, and commercialization of prescription medicines, with a strong emphasis on oncology, cardiovascular, renal, and metabolic diseases, as well as respiratory and immunology. The company collaborates with Daiichi Sankyo to develop Enhertu, a HER2-directed therapy.
YTD Price Performance: 6.80%
Average Trading Volume: 2,794,494
Technical Sentiment Consensus Rating: Strong Sell
Current Market Cap: £171.3B
For an in-depth examination of AZN stock, go to TipRanks’ Stock Analysis page.
